Key Decisions and Financial Results

The Board of Directors of Fredun Pharmaceuticals Limited at its meeting held on Thursday, November 05, 2026, considered, adopted, and approved the following items of business:

1. Approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half-Year Ended 30th September, 2026, along with the Limited Review Report issued by the statutory auditors, M/s. R.H. Nisar & Co.

2. Approved the proposal for making an application to National Stock Exchange of India Limited (NSE) for listing and trading of the equity shares of the Company on NSE, subject to applicable laws, regulations, and necessary approvals.

The trading window for trading in securities of the Company by insiders was closed from October 01, 2026, till the end of 48 hours after the declaration of the outcome of this Board Meeting, as per the earlier intimation dated September 28, 2026.

The Board Meeting commenced at 10:00 a.m. and concluded at 11:10 a.m.

Detailed Financial Performance (Standalone)

Income Statement Highlights (Quarter Ended 30.09.2026)

  • Net Sales/Income from Operations (Net of GST): ₹265.85 Cr (vs. ₹143.59 Cr in Q2 FY26; ₹227.76 Cr in Q1 FY27)
  • Other Operating Income: ₹1.78 Cr
  • Total Income from Operations: ₹267.64 Cr
  • Total Expenses: ₹237.73 Cr
  • Cost of Material Consumed: ₹239.81 Cr
  • Finance Costs: ₹8.78 Cr
  • Employee Benefits Expenses: ₹9.11 Cr
  • Depreciation and amortisation: ₹3.92 Cr
  • Profit Before Tax (PBT): ₹29.90 Cr (vs. ₹13.01 Cr in Q2 FY26)
  • Tax Expense: ₹11.08 Cr
  • Profit for the Period/Net Profit: ₹18.83 Cr (vs. ₹9.73 Cr in Q2 FY26)

Income Statement Highlights (Half-Year Ended 30.09.2026)

  • Net Sales/Income from Operations (Net of GST): ₹493.61 Cr (vs. ₹262.99 Cr in H1 FY26)
  • Other Operating Income: ₹2.27 Cr
  • Total Income from Operations: ₹495.88 Cr
  • Total Expenses: ₹445.39 Cr
  • Profit Before Tax (PBT): ₹50.49 Cr (vs. ₹22.05 Cr in H1 FY26)
  • Tax Expense: ₹18.50 Cr
  • Profit for the Period/Net Profit: ₹31.99 Cr (vs. ₹16.50 Cr in H1 FY26)

Earnings Per Share (EPS)

  • Basic EPS (Q2 FY27): ₹11.21
  • Diluted EPS (Q2 FY27): ₹11.07
  • Basic EPS (H1 FY27): ₹19.05
  • Diluted EPS (H1 FY27): ₹18.81

Share Capital and Shareholding Pattern (As of 30.09.2026)

  • Paid-up Equity Share Capital (Face Value ₹10/-): ₹16.90 Cr (1.69 Cr shares)
  • Public Shareholding: 56.38% (95,28,510 shares)
  • Promoter & Promoter Group Shareholding (Non-encumbered): 43.62% (73,71,159 shares)

Detailed Financial Performance (Consolidated)

Income Statement Highlights (Quarter Ended 30.09.2026)

  • Total Income from Operations: ₹267.64 Cr
  • Total Expenses: ₹237.98 Cr
  • Profit Before Tax (PBT): ₹29.65 Cr
  • Tax Expense: ₹11.08 Cr
  • Profit for the Period/Net Profit: ₹18.57 Cr

Income Statement Highlights (Half-Year Ended 30.09.2026)

  • Total Income from Operations: ₹495.88 Cr
  • Total Expenses: ₹445.68 Cr
  • Profit Before Tax (PBT): ₹50.20 Cr
  • Tax Expense: ₹18.50 Cr
  • Profit for the Period/Net Profit: ₹31.71 Cr

Earnings Per Share (EPS) - Consolidated

  • Basic EPS (Q2 FY27): ₹10.99
  • Diluted EPS (Q2 FY27): ₹10.92
  • Basic EPS (H1 FY27): ₹18.76
  • Diluted EPS (H1 FY27): ₹18.64

Balance Sheet Highlights (Standalone as of 30.09.2026)

  • Total Assets: ₹768.00 Cr (vs. ₹641.21 Cr as on 31.03.2026)
  • Non-Current Assets: ₹207.44 Cr (Property, Plant & Equipment: ₹148.26 Cr)
  • Current Assets: ₹560.56 Cr (Inventories: ₹372.45 Cr; Cash & Cash Equivalents: ₹55.15 Cr)
  • Total Equity: ₹331.32 Cr
  • Non-Current Liabilities: ₹102.39 Cr (Borrowings: ₹86.93 Cr)
  • Current Liabilities: ₹334.29 Cr (Borrowings: ₹159.71 Cr; Trade Payables: ₹122.32 Cr)

Cash Flow Statement Highlights (Standalone H1 FY27)

  • Net Cash Flow from Operating Activities: ₹19.25 Cr
  • Net Cash Used in Investing Activities: ₹(38.21) Cr (Purchase of Fixed Assets: ₹(38.37) Cr)
  • Net Cash Flow from Financing Activities: ₹9.22 Cr
  • Net Decrease in Cash and Cash Equivalents: ₹(9.75) Cr

Subsequent Events and Capital Structure Changes

  • The company allotted 1,10,25,380 fully paid-up bonus equity shares of ₹10 each on 16.07.2026 in the ratio of two equity shares for every one equity share held. Consequently, EPS for all comparative periods has been retrospectively adjusted.
  • During the half-year, the company allotted 1,60,533 equity shares pursuant to the conversion of an equal number of warrants against receipt of the applicable consideration. The resulting increase in paid-up equity share capital is reflected in these results.

Auditor's Review

  • The unaudited financial results were reviewed by the statutory auditors, R.H. Nisar & Co., who issued a limited review report with an unmodified conclusion for both standalone and consolidated results.
  • The consolidated results include the following subsidiaries: Fredun Retail Private Limited, One Pet Stop Private Limited, and Wagr Retail Private Limited.

Compliance and Governance

  • The results were reviewed by the Audit Committee and approved by the Board of Directors in their meetings held on November 05, 2026.
  • The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS).
  • The company operates in a single segment: "Pharmaceutical and Healthcare".